Metagenomic Sequencing Market Development And Business Intelligence
Seeking Alpha Analyst Since 2014
#Healthcare Consultant focusing on #TeleHealth #TeleMedicine #PatientPortals #CVIS #HCIT #MedicalRobots #Vaccines #MedicalDevices #WirelessHealth #Biotechnology
Summary
- Major factors influencing the growth of the market.
- Leading players & Business Strategies.
- Geographic Overview.
Market growth influenced due to following factors-
- The significant applications of metagenomics in various fields.
- The various initiatives and funding from government & private bodies for large-scale sequencing projects.
- The declining cost of sequencing.
Global market size-
According to research report metagenomic sequencing market is estimated to grow at a CAGR of 17.0% to reach USD 2.3 billion by 2024 from USD 1.0 billion in 2019.
Leading Players-
Illumina, Inc. (US), Thermo Fisher Scientific, Inc (US), QIAGEN N.V. (Netherlands), PerkinElmer (US), Oxford Nanopore Technologies Ltd. (UK), BGI Group (CHINA), Macrogen Inc. (South Korea), GENEWIZ (US), Eurofins Scientific (Luxembourg), Novogene Corporation (CHINA), Zymo Research Corporation (US), NuGEN Technologies, Inc (US), IntegraGen SA (France), Microsynth AG (Switzerland), and DNAStar, Inc (US) are some of the leading players operating in the metagenomic sequencing market.
For more details Download PDF Brochure Here
Geographic Overview -
The metagenomic sequencing market across four major geographies-North America, Europe, the Asia Pacific, and the Rest of the World. North America commanded the largest share of the metagenomic sequencing market in 2018.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.